PREDICTORS AND OUTCOMES OF ACUTE KIDNEY INJURY ASSOCIATED WITH COLISTIN
DOI:
https://doi.org/10.55519/JAMC-S4-12722Keywords:
acute kidney failure, acute kidney injury, anti-bacterial agents, colistin, drug toxicity, intensive care unit, polymyxins, risk factorsAbstract
Background: Colistin is a nephrotoxic drug. We aimed to determine factors predictive of acute kidney injury amongst patients on colistin and study its impact on mortality. Methods: This observational study was done on adult patients receiving colistin in intensive care unit. Exclusion criteria included use of colistin before shifting to intensive care unit, presence of acute kidney injury before starting colistin or unwillingness. Complete blood counts, serum creatinine, albumin, C-reactive protein and lactate were checked at admission. Renal function tests were repeated daily and urine output was regularly monitored. Sequential Organ Failure Assessment score was calculated after 24 hours of admission. Primary outcome was development of acute kidney injury based on KDIGO criteria. Results: There were 150 patients aged 45.17±13.24 years, with a median length of stay of 12 (10–15) days. Mortality rate in intensive care unit was 39.33% (59 patients). Acute kidney injury developed in 78 (52.00%) patients after a mean of 4.26±1.48 days. Serum C-reactive protein (OR=1.011; 95% confidence interval 1.000, 1.023) and lactate (OR=1.714; 95% confidence interval 1.015, 2.895) levels at admission were predictive of acute kidney injury. Serum C-reactive protein ≥92 mg/dl and lactate ≥2.15 mg/dl had sensitivity of 64.10% and 76.92% respectively, and specificity of 75.00% each for predicting acute kidney injury. Patients with AKI were 3.324 (95% confidence interval 1.660,6.656) times more likely to die. Conclusion: Acute kidney injury associated with colistin is a significant problem, and is predicted by serum C-reactive protein and lactate levels at admission.
References
1. Wang Z, Zhang L, Li S, Xu F, Han D, Wang H, et al. The relationship between hematocrit and serum albumin levels difference and mortality in elderly sepsis patients in intensive care units-a retrospective study based on two large database. BMC Infect Dis 2022;22(1):629.
2. Abu-Humaidan AHA, Ahmad FM, Al-Binni MA, Bani Hani A, Abu Abeeleh M. Characteristics of adult sepsis patients in the intensive care units in a tertiary hospital in Jordan: an observational study. Crit Care Res Pract 2021;2021:2741271.
3. Bonnet V, Dupont H, Glorion S, Aupee M, Kipnis E, Gerard JL, et al. Influence of bacterial resistance on mortality in intensive care units: a registry study from 2000 to 2013 (IICU Study). J Hosp Infect 2019;102(3):317–24.
4. Ustundag G, Oncel EK, Sahin A, Keles YE, Aksay AK, Ciftdogan DY. Colistin treatment for multidrug-resistant gram-negative infections in children: caution required for nephrotoxicity. Sisli Etfal Hastan Tip Bul 2022;56(3):427–34.
5. Bintang M, Nopparat J, Srichana T. In vivo evaluation of nephrotoxicity and neurotoxicity of colistin formulated with sodium deoxycholate sulfate in a mice model. Naunyn Schmiedebergs Arch Pharmacol 2023;396(11):3243–52.
6. Tabish M, Mahendran M, Ray A, Vikram NK. Colistin-induced acquired Bartter-like syndrome: an unusual cause of meltdown. BMJ Case Rep 2020;13(2):e232630.
7. Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol 2015;71(7):801–10.
8. Al Sulaiman K, Aljuhani O, Alhammad AM, Al Aamer K, Alshehri S, Alhuwahmel A, et al. The potential role of adjunctive ascorbic acid in the prevention of colistin-induced nephrotoxicity in critically ill patients: A retrospective study. Saudi Pharm J 2022;30(12):1748–54.
9. Gul H, Arshad AR, Khan HA, Ijaz MM. Impact of acute kidney injury on in-hospital outcomes amongst critically ill patients. J Pak Soc Intern Med 2023;4(1):24–28.
10. Deniz M, Alişik M. Risk factors and prognosis for the development of acute kidney injury in patients using colistin in the intensive care unit: A retrospective cohort study. Medicine (Baltimore) 2024;103(2):e36913.
11. Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol 2010;5(9):1315–6.
12. Sisay M, Hagos B, Edessa D, Tadiwos Y, Mekuria AN. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury. Pharmacol Res 2021;163:105328.
13. Wagenlehner F, Lucenteforte E, Pea F, Soriano A, Tavoschi L, Steele VR, et al. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. Clin Microbiol Infect 2021: S1198-743X(20)30764–3.
14. Babar ZU, Dodani SK, Nasim A. Treatment outcome and adverse effects of colistin in adult patients with carbapenem-resistant gram-negative bacteremia from Pakistan. Int J Infect Dis 2021;106:171–5.
15. Ambreen G, Salat MS, Hussain K, Raza SS, Ali U, Azam I, et al. Efficacy of colistin in multidrug-resistant neonatal sepsis: experience from a tertiary care center in Karachi, Pakistan. Arch Dis Child 2020;105(9):830–6.
16. Aitullina A, Krumina A, Svirskis S, Purvina S. Colistin use in patients with extreme renal function: from dialysis to augmented clearance. Medicina (Kaunas) 2019;55(2):33.
17. Chang K, Wang H, Zhao J, Yang X, Wu B, Sun W, et al. Risk factors for polymyxin B-associated acute kidney injury. Int J Infect Dis 2022;117:37–44.
18. Arrayasillapatorn N, Promsen P, Kritmetapak K, Anunnatsiri S, Chotmongkol W, Anutrakulchai S. Colistin-induced acute kidney injury and the effect on survival in patients with multidrug-resistant gram-negative infections: significance of drug doses adjusted to ideal body weight. Int J Nephrol 2021;2021:7795096.
19. Min KL, Son ES, Kim JS, Kim SH, Jung SM, Chang MJ. Risk factors of colistin safety according to administration routes: Intravenous and aerosolized colistin. PLoS One 2018;13(11):e0207588.
20. Liu J, Shu Y, Zhu F, Feng B, Zhang Z, Liu L, et al. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis. J Glob Antimicrob Resist 2021;24:136–47.
21. Balkan, II, Dogan M, Durdu B, Batirel A, Hakyemez IN, Cetin B, et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis 2014;46(10):678–85.
22. Jin J, Zhu J, Zhu Z, Kim WY, O'Rourke J, Lin Z, et al. Clinical efficacy and nephrotoxicity of intravenous colistin sulfate in the treatment of carbapenem-resistant gram-negative bacterial infections: a retrospective cohort study. Ann Transl Med 2022;10(20):1137.
23. Moghnieh R, Husni R, Helou M, Abdallah D, Sinno L, Jadayel M, et al. The prevalence and risk factors of acute kidney injury during colistin therapy: a retrospective cohort study from Lebanon. Antibiotics (Basel) 2023;12(7):1183.
24. Almutairy R, Aljrarri W, Noor A, Elsamadisi P, Shamas N, Qureshi M, et al. Impact of colistin dosing on the incidence of nephrotoxicity in a tertiary care hospital in Saudi Arabia. Antibiotics (Basel) 2020;9(8):485.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Bilal Ahmad, Abdul Rehman Arshad, Arshad Naseem, Abdul Rasheed, Zulqarnain Saleem, Sohail Sabir
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
